Previous 10 | Next 10 |
Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced that it has entered into a binding agreement for the acquisition of the exclusive U.S. commercial rights to five FD...
Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic prescription therapies, and iOR Partners, the pioneer in office-based surgery in the field of ophthalmology, today jointly announced the expan...
Sienna Harrow Health, Inc. (HROW) Q3 2022 Earnings Conference Call November 14, 2022 4:45 PM ET Company Participants Jamie Webb – Director-Communications and Investor Relations Mark L. Baum – Chief Executive Officer Andrew Boll – Chief Financ...
Harrow Health press release ( NASDAQ: HROW ): Q3 GAAP EPS of -$0.24 misses by $0.23 . Revenue of $22.8M (+21.9% Y/Y) misses by $0.34M . For further details see: Harrow Health GAAP EPS of -$0.24 misses by $0.23, revenue of $22.8M misses by $0.34M
Selected Recent Highlights: FDA approval of IHEEZO™ for ocular surface anesthesia Launch of Fortisite™, fortified antibiotics Launch of atropine.com™ compounded atropine portal Revenues of $22.8 million, up 22% over $18.7 million for the prior ...
Summary Harrow Health, Inc. is a well-managed ophthalmic medicines business. The company has remained profitable for a number of years. Harrow Health expects to double revenues in 2-3 years. For further details see: Harrow Health: Profitable Ophthalmi...
Announces Nationwide Availability of Compounded Atropine Formulations Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced the launch of atropin...
Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced that it will release its financial results for the third quarter ended September 30, 2022, on Monday, Nov...
Top-Line Results Expected by Year-End Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel approaches for procedural sedation and analgesia, today announced the dosing of the last patient in its Phase 2 pivotal efficacy and safety study for it...
Harrow ( NASDAQ: HROW ) said Wednesday it sold its non‑ophthalmic compounding business to Innovation Compounding Pharmacy, an affiliate of Revelation Pharma. Terms were not disclosed. The sale includes formulations, customer accounts and other related assets. ...
News, Short Squeeze, Breakout and More Instantly...
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 8, 2024 Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2024, on Wednesday, August...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual Meeting, taking place in Stockholm, Sweden, from July 17-20, 2024. The ASRS Annual Meeting brings tog...
Contract Enhances Purchasing Power for 340B Prime Vendor Program (PVP) Participants; Aligns with Harrow’s Mission to Make Its Products Accessible and Affordable Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, ...